It looks like Biogen Inc.’s Nrf2 activator, Skyclarys (omaveloxolone), will maintain its status as the sole therapy approved for treating patients with Friedreich’s ataxia (FA), at least for now. The ...
PTC Therapeutics (PTCT) submitted the vatiquinone New Drug Application, or NDA, for the treatment of children and adults living with Friedreich ataxia, or FA, to the FDA. The vatiquinone NDA is based ...
Several months after forging a fresh path forward for its troubled Friedreich ataxia (FA) drug vatiquinone, PTC Therapeutics is back with some much-needed positive data. The candidate passed muster by ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
PTC Therapeutics has cued up no fewer than three clinical trial readouts this quarter that could lead to new regulatory filings – but the latest for vatiquinone in inherited nerve disorder Friedreich ...
New York, USA, July 16, 2024 (GLOBE NEWSWIRE) -- Friedreich's Ataxia Market to Grow at a Substantial Growth Rate by 2034, Examines DelveInsight | Key Companies - Retrotope, PTC Therapeutics, Minoryx ...
WARREN, N.J., Oct. 8, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) provided today several positive updates on the vatiquinone Friedreich ataxia (FA) program. The pre-specified endpoint ...
The FDA rejected PTC Therapeutics' NDA for vatiquinone, citing insufficient efficacy evidence and requiring an additional study for resubmission. The MOVE-FA trial, a Phase II/III study, failed to ...
After the FA failure, announced in May 2023, PTC cut staff and conducted a pipeline prioritization. Then in June, vatiquinone failed again in MDAS, causing PTC to move on from the indication.
The U.S. Food and Drug Administration has turned away PTC Therapeutics' proposed vatiquinone treatment for the rare, inherited neurodegenerative disorder Friedreich's ataxia over concerns about the ...
WARREN, N.J. - The U.S. Food and Drug Administration has issued a Complete Response Letter rejecting PTC Therapeutics’ (NASDAQ:PTCT) New Drug Application for vatiquinone, a treatment for Friedreich’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results